

“Supplementary Material”

Supplementary Table 1. Patient background by presence or absence of chronic lung disease

Supplementary Table 1. Patient background by presence or absence of chronic lung disease

Variable	With chronic lung disease (n=83)	Without chronic lung disease (n=192)	<i>p</i> -value
Gender, male (%)	23/83 (27.7%)	29/192 (15.1%)	0.0186*
Age at starting bDMARD/tsDMARD (IQR)	63 (55–70)	57 (46–65)	0.0025*
Disease duration until bDMARD/tsDMARD initiation (month)	65.5 (20.8–176.8)	47 (12–121.5)	0.0912
DAS28-CRP (IQR)	4.96 (4.11–5.80)	4.47 (3.58–5.39)	0.0237*
DAS28-ESR (IQR)	5.46 (4.61–6.40)	5.13 (4.25–6.07)	0.0392*
Body weight (kg) (IQR)	52.2 (46.3–58.3)	52.0 (46.2–59.7)	0.7608
No. of previous bDMARD/tsDMARD uses (IQR)	1 (1–2)	1 (1–2)	0.808
Prophylaxis with an antitubercular agent	64/83 (77.1%)	131/192 (68.2%)	0.1501
Prophylaxis with TMP-SMX	3/83 (3.61%)	3/192 (1.56%)	0.3705
No. of PSL ≥5mg users	33/83 (39.8%)	82/192 (42.7%)	0.7614

MTX use	39/83 (47.0%)	124/192 (64.6%)	0.0230*
Diabetes mellitus (%)	16/83 (19.3%)	17/192 (8.85%)	0.0245*
Initiation of bDMARD/tsDMARD before 2010	33/83 (39.8%)	90/192 (46.9%)	0.2931

DAS28: Disease Activity Score including 28-joint count, CRP: C-reactive protein, bDMARD: biological disease-modifying antirheumatic drug, tsDMARDs: targeted synthetic disease-modifying antirheumatic drug, MTX: methotrexate, TMP-SMX: trimethoprim-sulfamethoxazole. Values are median (interquartile: IQR). The *p*-values were determined using the nonparametric Wilcoxon signed rank test and Fisher's exact test.